Xience V everolimus-eluting coronary stent

Area of Science:

• Cardiovascular Medicine
• Biomedical Engineering
• Interventional Cardiology

Background:

• Drug-eluting stents (DES) are crucial for treating coronary artery disease, aiming to prevent restenosis common with bare-metal stents.
• Early-generation DES faced challenges regarding device deliverability and patient safety.
• The Xience V stent represents a second-generation DES designed to address these concerns.

Purpose of the Study:

• To evaluate the efficacy and safety of the second-generation Xience V everolimus-eluting stent.
• To compare the Xience V stent's performance against first-generation paclitaxel-eluting stents.
• To assess the Xience V stent in complex and high-risk patient populations.

Main Methods:

• The Xience V stent utilizes a cobalt-chromium platform with an everolimus-eluting polymer coating.
• Efficacy was assessed through low rates of angiographic restenosis.
• Randomized trials compared Xience V against the Taxus stent, with repeat revascularization rates as a key endpoint.

Main Results:

• The Xience V stent demonstrated low rates of angiographic restenosis.
• Randomized trials indicated a reduction in repeat revascularization rates when compared to the Taxus stent.
• Ongoing trials and registries are investigating its use in 'all-comer' and high-risk patient groups.

Conclusions:

• The Xience V everolimus-eluting stent shows promising efficacy and improved outcomes in coronary artery disease treatment.
• It appears to offer advantages over first-generation DES, particularly in reducing repeat revascularization.
• Further evaluation in diverse patient populations will continue to define its role in interventional cardiology.